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ABSTRACT
Background: Vascular calcification is an important stage in atherosclerosis. During this stage, vascular smooth 
muscle cells (VSMC) synthesize many osteogenic factors such as osteonectin (encoded by SPARC). Oxidative 
stress plays a critical role in atherosclerosis progression, and its accumulation in the vascular wall stimulates the 
development of atherosclerosis and vascular calcification. The osteonectin overexpression has been observed in the 
arterial wall during the course of atherosclerosis. However, the regulatory mechanism of oxidized low density 
lipoprotein (oxLDL)-mediated vascular calcification remains to be clarified. The aim of this study was to 
investigate the effect of oxLDL on the osteonectin gene expression through the Runx2 transcription factor.
Methods: In this experimental study, VSMC were cultured in F-12K media and then treated with oxLDL. The 
expression of Runx2 and osteonectin genes was determined by real-time PCR method. Protein levels were 
investigated by the western blotting technique. The Runx2 gene was knocked down using siRNA in order to 
determine whether Runx2 regulates the osteonectin expression in VSMC induced by oxLDL. Then transfected cells 
were treated with oxLDL, and the expression levels of Runx2 and osteonectin were determined again. Results: 
oxLDL was found to increase Runx2 and osteonectin gene expression (4.8 ± 0.47- and 9.2 ± 1.96-fold,
respectively) after 48 h. Western blotting analysis confirmed the induced levels of Runx2 and osteonectin proteins. 
However, oxLDL-induced osteonectin expression was not observed to be blocked by Runx2 knockdown.
Conclusion: The up-regulation of osteonectin by oxLDL is independent of Runx2, and it may be mediated by other 
transcription factors. Iran. Biomed. J. 19 (3): 160-164, 2015
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INTRODUCTION
ascular calcification, defined as the pathologic 
deposition of mineral in the vascular system, is 
generally observed in atherosclerosis [1]. 
Vascular calcification is widely believed to be an 
active process similar to bone formation. In this regard, 
bone-related proteins, such as osteonectin and 
osteocalcin, as well as bone morphogenic proteins have 
been reported in calcified vascular tissues [2, 3].
Osteonectin, which is known as secreted protein 
acidic and rich in cysteine (SPARC), is a bone-related 
protein that has a major role in bone development and 
mineralization. It has high affinity for hydroxyapatite 
and calcium [4]. Like other bone-related proteins, 
osteonectin is expressed in the arterial wall during 
atherosclerosis progress, specifically during the 
calcification of the atherosclerotic plaque [3, 5, 6]. The 
presence of this protein in advanced human 
atherosclerotic plaques suggests that osteonectin may 
act as a promoter of vascular calcification [6]. The 
osteonectin gene is strongly expressed in aortic 
stenosis and participates in the neovascularization of 
aortic stenosis valves [7]. This protein also plays an 
important role in atherogenesis and can serve as a new 
biomarker of atherosclerosis and calcinosis of coronary 
arteries [8].
Oxidative stress is a vital factor in the progression of 
vascular calcification [9] and activates the genes that 
lead to the increased deposition of extracellular matrix 
proteins [10]. Oxidized low-density lipoprotein 
(oxLDL) accumulation in the vascular wall stimulates 
the development of atherosclerosis and vascular 
calcification [11]. 
Runx2 is a key transcription factor necessary for 
osteoblast differentiation and regulation of the 
expression of many osteogenic factors [12]. In vitro
studies have demonstrated that Runx2 has an essential 
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role in oxidative stress-induced vascular smooth 
muscle cells (VSMC) calcification, and Runx2 alone is 
sufficient to induce VSMC calcification [12,13]. 
However, the potential link between the osteonectin
gene expression and oxidative stress-induced vascular 
calcification has not been examined. The current study 
was launched to investigate the hypothesis that oxLDL 
up-regulates osteonectin expression in human VSMC
through Runx2.
MATERIALS AND METHODS
The human aorta VSMC and F12K media were 
purchased from Pasteur Institute of Iran (Tehran), 
OxLDL from Biomedical Technologies (Stoughton, 
MA, USA). cDNA synthesis kit, DNase, and SYBR 
Green PCR Master Mix were obtained from Thermo 
Fisher Scientific (Waltham, MA, USA), Trizol from 
Invitrogen (USA), siRNA (S2455,S2456), Opti-MEM 
media, and lipofectamine from Invitrogen (Ambion, 
Austin, TX, USA), FITC (fluorescein isothiocyanate)-
conjugated siRNA from Santa Cruz Biotechnology
(USA), anti-Runx2 (ab102711), anti-SPARC 
(ab55847), anti-beta-actin (ab70165), and secondary 
antibody (ab6721) from Abcam (Cambridge, UK), and 
3, 3’-5, 5’-tetramethylbenzidine (BM blue) from 
Roche Diagnostic (Mannheim, Germany).
Cell culture, RNA isolation, and cDNA synthesis. In 
this experimental study, human aorta VSMC were 
cultured in F-12K media containing 10% fetal bovine 
serum. The media contained 0.05 mg/mL ascorbic acid, 
0.01 mg/mL insulin, 0.01 mg/mL transferrin, 10 ng/mL 
sodium selenite, 0.03 mg/mL endothelial cell growth 
supplement, 10 mM HEPES, 10 mM TES, 100 U/mL 
penicillin, 100 µg/mL streptomycin, and 0.01%
amphotericin B. The cells were incubated at 37°C in a 
humidified atmosphere containing 5% CO2. Cell 
growth was followed daily, and cells from passages 3-7
were used for all experiments. Cells were cultured with 
10 mM β-glycerophosphate for 12 days to induce 
VSMC calcification, and then they were seeded in 12-
well plates at an initial density of 10,000 cells per well. 
Having being achieved approximately 80% confluence, 
the cells were transferred to media containing 100
µg/mL oxLDL [14]. The cells cultured in the media 
containing β-glycerophosphate without oxLDL were 
used as the control. Total RNA was isolated using 
Trizol according to the manufacturer's instructions 
after 24 and 48 h. RNA was quantified using a 
NanoDrop 2000C spectrophotometer (Thermo Scientifi
c, USA) and treated with DNase. Then cDNA was 
synthesized from 0.5 µg total RNA using a random 
primer and the ReverAid First Standard cDNA 
Synthesis kit (Thermo Scientific, Canada).
Real-time PCR. Quantitative real-time PCR was 
performed using the Rotor-Gene 3000 real-time DNA 
amplification system (Corbett Research, Australia) and 
SYBR green method. The sequences of primers used 
for real-time PCR are listed in Table 1. The 
amplification was carried out as follows: initial enzyme 
activation at 94°C for 10 min, then 40 cycles of 95°C 
for 15 s, 59°C for 20 s, and 72°C for 30 s. The 
quantitation of data was performed using the 
comparative CT (ΔΔCT) method by glyceraldehyde-3-
phosphate dehydrogenase gene expression as an 
endogenous reference.
Western blotting. After appropriate treatment, 
VSMC were washed twice with cold PBS and lysed in 
ice-cold radio immune precipitation assay buffer (6×)
containing protease inhibitor cocktail. The homogenate 
was incubated in lysis buffer for 30 min and then 
centrifuged at 12,000 ×g at 4°C for 10 min. The 
supernatant was used as the total cell lysate. Protein 
concentration was measured spectrophoto-metrically 
by a NanoDrop, and the equal amounts of protein from 
each sample were subjected to blotting. Protein lysate 
was mixed with SDS loading buffer (0.125 M Tris-
HCl 4%, SDS 20%, glycine 10%, and 2-mercapto-
ethanol), followed by boiling for 5 min and separated 
by 12% SDS-PAGE. The separated proteins were then 
transferred to polyvinylidene difluoride membranes in 
Tris-Glycine buffer (25mM Tris-base, 192 mM 
glycine, 20% methanol) for 2 h at 120 V. The 
membranes were blocked using blocking solution (5%
nonfat dried milk in Tris-buffered saline and 0.1%
Tween-20) at 4ºC overnight. Then they were incubated 
in Tween-20 containing the primary rabbit polyclonal 
anti-SPARC (1 μg/mL) and primary rabbit polyclonal 
anti-Runx2 (1:2,000) at room temperature for 2 h.
After washing, the membrane was incubated with goat 
anti-rabbit IgG horseradish peroxidase conjugate
(1:10,000) at room temperature for 90 min. Finally, the 
color was developed with the addition of 3,3’,5,5’-
tetramethyl-benzidine membrane peroxidase substrate.
The color reaction was stopped by washing the 
membranes with distilled water. Cell lysates were 
detected on a separate membrane with actin as a 
loading control.
     Table 1. Primer sequences and product lengths
Genes Primer sequences (5'–3')
Product 
length (bp)
Runx2 F: CGATCTGAGATTTGTGGGCC
R: GGGAGGATTTGTGAAGACGG 76
Osteonectin
F: TCTTCCCTGTACACTGGCAGTTC
R: AGCTCGGTGTGGGAGAGGTA 73
GAPDH
F: ACACCCACTCCTCCACCTTTG
R: TCCACCACCCTGTTGCTGTAG
112
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; F, forward; R 
reverse
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Runx2 RNA interference. To knockdown Runx2, we
used two siRNA (ID: s2455 and s2456). Runx2
siRNA, s2455 and s2456, are located in the region of 
the Runx2 transcript that codes for amino acids 910-
928 and 1663-1683, respectively. The oligonucleotide 
sequences were as follows: s2455: 5'-CUUGAUGAC
UCUAAACCUATT-3' and 5'-UAGGUUUAGAGUC
AUCAAGCT-3', s2456: 5'-CCAAAUUUGCCUA
ACCAGATT-3' and 5'- UCUGGUUAGGCAAAUUU
GGAT-3'. The cells were seeded in a 24-well plate at a 
density of 20,000 cells/well in growth media without 
antibiotics. After 24 h, the cells were transfected with 
RNAi duplex-Lipofectamine RNAiMAX complexes 
made in Opti-MEM according to the manufacturer’s 
instructions. siRNA (10 nM each) was used for all 
transfections. siRNA transfection efficiency was 
observed by the uptake of FITC-labeled siRNA
sequence and scramble oligoribonucleotide duplex that 
was not homologous to any mammalian genes was 
used as a control. After 24 h, the transfection media 
were removed, and the cells were incubated for an 
additional 24 h in normal growth media and then 
treated with oxLDL (100 µg/mL). The cells were 
harvested for mRNA and protein extraction after 48 h.
Statistical analysis. Data were presented as the mean 
± SEM of three independent experiments. Statistical 
analysis was carried out using nonparametric Kruskal-
Wallis test, and pairwise comparisons between the 
groups were performed by Mann-Whitney test. All 
statistical analyses were performed by Graph Pad 
Prism5 software v5.01, and all data were presented as 
mean ± SEM, and P < 0.05 was regarded as the level 
of significance.
RESULTS
Effect of oxLDL on osteonectin and Runx2
expression. VSMC were treated with 100 µg/mL 
oxLDL to investigate the effect of oxLDL on Runx2
and osteonectin expression. The expression of 
osteonectin and Runx2 in mRNA and protein levels 
were analyzed using real-time PCR and western 
blotting, respectively. Our result indicated that oxLDL 
increased Runx2 expression (2.29 ± 0.39- and 4.8 ±
0.47-fold) and osteonectin expression (1.49 ± 0.35- and 
9.2 ± 1.96-fold) after 24 and 48 h, respectively (Fig. 1). 
siRNA  transfection. To determine whether Runx2
knockdown may affect oxLDL-induced expression of
osteonectin, we compared the expression of the
osteonectin gene in control and Runx2-knockdown 
cells. First, the cells were transfected with Runx2
treated with oxLDL. Transfection efficacy was
determined using FITC-labeled siRNA and
fluorescence microscopy. The transfection efficiency
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Fig. 1. The up-regulation of Runx2 and osteonectin 
expression in VSMC by oxLDL. The cells were treated by 
oxLDL for 24 and 48 h. The expressions of Runx2 (A) and 
osteonectin (B) against control were determined by real-time 
PCR after treatment. Data were expressed as means ± SEM of 
three independent experiments. *P < 0.05 compared with 
control; (C) Protein expression levels of Runx2 and osteonectin 
were determined by western blotting analysis against control 
(beta-actin). 
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was > 70% as determined by fluorescence. Real-time 
PCR and western blotting results showed that Runx2
siRNA clearly suppressed both basal and oxLDL-
induced Runx2 expression (Fig. 2A and 2C). However, 
oxLDL-induced osteonectin expression was not 
blocked by Runx2 knockdown (Fig. 2B and 2C). These 
results indicated that oxLDL-induced osteonectin
expression was not dependent on Runx2 expression, 
suggesting that up-regulation of osteonectin by oxLDL 
is independent of Runx2, and it may be mediated by 
other transcription factor.
DISCUSSION
In this study, we showed that oxLDL increased the 
expression of Runx2 and osteonectin genes in VSMC, 
and silencing of Runx2 had no effect on the expression 
of the osteonectin gene. 
Vascular calcification is a process actively regulated 
by osteogenic factors [15, 16]. However, the 
mechanisms underlying the up-regulation of these 
factors have not been fully understood. Osteonectin is 
an osteogenic marker, and the presence of this protein 
in advanced human atherosclerotic plaques has been 
already described [6]. We found that the stimulation of 
VSMC with oxLDL increased osteonectin protein 
levels. This observation indicates that oxLDL-induced 
osteonectin expression may induce vascular osteogenic 
changes associated with atherosclerosis. It is known 
that oxLDL accumulation in the vascular wall prompts 
the development of atherosclerosis and vascular 
calcification [11] and based on our finding, oxLDL 
contributes to the development of vascular calcification 
by the up-regulation of osteogenic factors such as 
osteonectin.  
Another result of this study was that oxLDL 
increased the expression of Runx2, which is a 
transcription factor with a central role in osteoblast 
differentiation and bone formation. Runx2 is a pivotal 
player in VSMC calcification in vitro [13, 17], and its 
elevated protein levels in atherosclerotic plaque also 
suggests its possible main role in vascular calcification 
[18].
A recent study has demonstrated that Runx2 deficiency
eliminates the oxidative stress-induced expression of 
osteogenic markers such as alkaline phosphatase and
osteocalcin [19]. Also, another study has indicated that 
Runx2 suppression reduces the transcription of 
osteoblast markers such as osteonectin, osteocalcin,
and alkaline phosphatase [20]. Although we had 
hypothesized that oxLDL would increase the
osteonectin expression by up-regulating Runx2
expression, our findings showed otherwise; Runx2 did
not mediate oxLDL effect on osteonectin expression.
          0
1
2
3
4
5
*
* *
      
        0
2
4
6
8
10
12
**
      
Fig. 2. A decrease in Runx2 expression by the Runx2
knockdown. After the transfection of cells with Runx2 siRNA or 
control siRNA (scramble), the cells were treated with or without 
oxLDL (100 µg/mL) for 48 h. Then real-time PCR (A and B) or 
western blotting analysis (C) was performed. Data were 
expressed as means ± SEM of three experiments. *P < 0.05 was 
compared with control.
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Therefore, other factors should mediate the effect of 
oxLDL on the expression of osteonectin. Osterix is 
another osteoblast transcription factor involved in the 
regulation of numerous osteoblast genes, including 
osteocalcin, osteonectin, osteopontin, bone sialo-
protein, and collagen type I [21]. 
Since oxLDL promotes osteoblast differentiation in 
VSMC by up-regulating osterix expression [14], it 
seems that other regulators such as osterix which 
mediates the effect of oxLDL on osteonectin
expression. However, future studies are needed to 
confirm the hypothesis.
In summary, the findings of this study demonstrated 
that oxLDL increased the expression of Runx2 and 
osteonectin genes in VSMC. Neverthless, oxLDL-
induced osteonectin expression was not blocked, and it
may be mediated by other transcription factor such as 
osterix.
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